# PRESS RELEASE 2016

- # [Ferring and IMAB sign licensing agreement granting IMAB exclusive rights in Asia to olamkicept for the treatment of autoimmune disease](/content/ferring-and-imab-sign-licensing-agreement-granting-imab-exclusive-rights-in-asia-to-olamkicept-for-the-treatment-of-autoimmune-disease/index.html)

By [pulse](/content/author/pulse/index.html) in [PRESS RELEASE 2016](/content/category/press-release-2016/index.html) on 19 December 2016

Ferring Pharmaceuticals and IMAB today announced that they have signed a licensing agreement which grants IMAB exclusive rights…

- # [Ferring receives EU approval for REKOVELLE® (follitropin delta)](/content/ferring-receives-eu-approval-for-rekovelle-follitropin-delta/index.html)

By [pulse](/content/author/pulse/index.html) in [PRESS RELEASE 2016](/content/category/press-release-2016/index.html) on 13 December 2016

Ferring Pharmaceuticals announced today that the European Commission (EC) has granted marketing authorisation for REKOVELLE®…

- # [Ferring Pharmaceuticals collaborates with MetaboGen AB on development of microbiome-based treatment for intrahepatic cholestasis of pregnancy (ICP)](/content/ferring-pharmaceuticals-collaborates-with-metabogen-ab-on-development-of-microbiome-based-treatment-for-intrahepatic-cholestasis-of-pregnancy-icp/index.html)

By [pulse](/content/author/pulse/index.html) in [PRESS RELEASE 2016](/content/category/press-release-2016/index.html) on 05 December 2016

Ferring Pharmaceuticals and MetaboGen AB today announced a multi-year research collaboration…

- # [Ferring Pharmaceuticals and Aché Laboratórios Farmacêuticos collaborate on nanotechnology R&D platform](/content/ferring-pharmaceuticals-and-ache-laboratorios-farmaceuticos-collaborate-on-nanotechnology-rd-platform/index.html)

By [pulse](/content/author/pulse/index.html) in [PRESS RELEASE 2016](/content/category/press-release-2016/index.html) on 30 November 2016

Ferring Pharmaceuticals and Aché Laboratórios Farmacêuticos today announced a long-term collaboration aimed at improving…

- # [Ferring receives positive CHMP opinion for REKOVELLE® (follitropin delta)](/content/ferring-receives-positive-chmp-opinion-for-rekovelle-follitropin-delta/index.html)

By [pulse](/content/author/pulse/index.html) in [PRESS RELEASE 2016](/content/category/press-release-2016/index.html) on 17 October 2016

Ferring Pharmaceuticals announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion…

- # [Ferring Pharmaceuticals and North Zealand University Hospital mark first milestone in innovative IBD collaboration](/content/ferring-pharmaceuticals-and-north-zealand-university-hospital-mark-first-milestone-in-innovative-ibd-collaboration/index.html)

By [pulse](/content/author/pulse/index.html) in [PRESS RELEASE 2016](/content/category/press-release-2016/index.html) on 31 August 2016

Ferring Pharmaceuticals and North Zealand University Hospital (Nordsjællands Hospital) yesterday formally inaugurated…

- # [Ferring Pharmaceuticals Acquires Exclusive Licensing Rights to Condoliase from Seikagaku Corporation](/content/ferring-pharmaceuticals-acquires-exclusive-licensing-rights-to-condoliase-from-seikagaku-corporation/index.html)

By [pulse](/content/author/pulse/index.html) in [PRESS RELEASE 2016](/content/category/press-release-2016/index.html) on 29 August 2016

Ferring Pharmaceuticals announced today that it has signed an agreement with Seikagaku Corporation granting Ferring the exclusive worldwide rights…

- # [Ferring announces Phase 3 data for investigational human recombinant FSH with individualised dosing regimen at the 32nd Annual Meeting of ESHRE®](/content/ferring-announces-phase-3-data-for-investigational-human-recombinant-fsh-with-individualised-dosing-regimen-at-the-32nd-annual-meeting-of-eshre/index.html)

By [pulse](/content/author/pulse/index.html) in [PRESS RELEASE 2016](/content/category/press-release-2016/index.html) on 04 July 2016

Data from the Phase 3 ESTHER trials (Evidence-based Stimulation Trial with Human recombinant follicle-stimulating hormone…

- # [Ferring Pharmaceuticals announces approval of new tailored dosing regimen in the PICOPREP® (sodium picosulfate, magnesium oxide, citric acid) label in MRP countries in Europe](/content/ferring-pharmaceuticals-announces-approval-of-new-tailored-dosing-regimen-in-the-picoprep-sodium-picosulfate-magnesium-oxide-citric-acid-label-in-mrp-countries-in-europe/index.html)

By [pulse](/content/author/pulse/index.html) in [PRESS RELEASE 2016](/content/category/press-release-2016/index.html) on 27 June 2016

Ferring Pharmaceuticals has successfully finalised a Mutual…

- # [Ferring demonstrates commitment to R&D investment through expanded Innovation Grants Program](/content/ferring-demonstrates-commitment-to-rd-investment-through-expanded-innovation-grants-program/index.html)

By [pulse](/content/author/pulse/index.html) in [PRESS RELEASE 2016](/content/category/press-release-2016/index.html) on 21 June 2016

The Ferring Innovation Grants Program, which is now open for applications, has been significantly expanded as part of Ferring’s continued commitment to investing in research and development…